acquired
Stage
About
Juno Therapeutics is a biotechnology company that developed engineered cell-based immunotherapies, including CAR-T and TCR therapies, for the treatment of cancer. The company was acquired by Celgene in 2018.
Explore Juno Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.